Michael Mitchell, Skirkanich Assistant Professor of Innovation in the Department of Bioengineering, is the recipient of the Controlled Release Society (CRS) 2019 T. Nagai Postdoctoral Research Achievement Award, which comes with a $3,000 honorarium.
According to the CRS website, “The Controlled Release Society T. Nagai Postdoctoral Research Achievement Award has been established to recognize an individual postdoctoral candidate who has recently completed outstanding postdoctoral research in controlled release science and technology, and the postdoc’s advisor who played an integral role in those achievements.”
Mitchell and his postdoctoral advisor at MIT, Robert Langer, will receive the award at the 2019 CRS annual meeting this July in Valencia, Spain.
The sole recipient of this award, Mitchell was recognized for his work on engineering controlled release technologies for cancer gene therapy and immunotherapy. Mitchell focuses on improving the way drugs are delivered within the body by combining approaches from engineering, biology, machine learning, and data science to better target diseased cells. Mitchell’s work helps to lay the foundation for a new class of therapeutic strategies against hematologic cancers such as multiple myeloma and leukemia.
For this research, Mitchell also received the Burroughs Wellcome Fund Career Award at the Scientific Interface in 2016, the NIH Director’s New Innovator Award in 2018, and a Rising Star Award in Cellular and Molecular Bioengineering from the Biomedical Engineering Society in 2019. He joined the Penn faculty in January 2018 after completing an NIH NCI postdoctoral fellowship at the Koch Institute for Integrative Cancer Research at MIT.